Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope

BackgroundCost-effectiveness acceptability curves (CEACs) describe the probability that a new treatment or intervention is cost-effective. The net benefit regression framework (NBRF) allows cost-effectiveness analysis to be done in a simple regression framework. The objective of the paper is to illustrate how net benefit regression can be used to construct a CEAC.MethodsOne hundred patients referred for ambulatory monitoring with syncope or presyncope were randomized to a one-month external loop recorder (n = 49) or 48-hour Holter monitor (n = 51). The primary endpoint was symptom-rhythm correlation during monitoring. Direct costs were calculated based on the 2003 Ontario Health Insurance Plan (OHIP) fee schedule combined with hospital case costing of labour, materials, service and overhead costs for diagnostic testing and related equipment.ResultsIn the loop recorder group, 63.27% of patients (31/49) had symptom recurrence and successful activation, compared to 23.53% in the Holter group (12/51). The cost in US dollars for loop recording was $648.50 and $212.92 for Holter monitoring. The incremental cost-effectiveness ratio (ICER) of the loop recorder was $1,096 per extra successful diagnosis. The probability that the loop recorder was cost-effective compared to the Holter monitor was estimated using net benefit regression and plotted on a CEAC. In a sensitivity analysis, bootstrapping was used to examine the effect of distributional assumptions.ConclusionThe NBRF is straightforward to use and interpret. The resulting uncertainty surrounding the regression coefficient relates to the CEAC. When the link from the regression's p-value to the probability of cost-effectiveness is tentative, bootstrapping may be used.

[1]  T. Gibson,et al.  Diagnostic efficacy of 24-hour electrocardiographic monitoring for syncope. , 1984, The American journal of cardiology.

[2]  A. Krahn,et al.  The Costs of Recurrent Syncope of Unknown Origin in Elderly Patients , 1999, Pacing and clinical electrophysiology : PACE.

[3]  A. Skanes,et al.  Is ambulatory monitoring for "community-acquired" syncope economically attractive? A cost-effectiveness analysis of a randomized trial of external loop recorders versus Holter monitoring. , 2005, American heart journal.

[4]  L. White,et al.  The Clinical Efficacy Assessment Project of the American Collegeof Physicians , 1985, International Journal of Technology Assessment in Health Care.

[5]  W. Kapoor,et al.  Evaluation and management of the patient with syncope. , 1992, JAMA.

[6]  S. Yusuf,et al.  Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. , 2006, American heart journal.

[7]  J. Dimant,et al.  Importance of holter monitoring in patients with periodic cerebral symptoms , 1977, Annals of neurology.

[8]  Mark Linzer,et al.  CLINICAL GUIDELINE: Diagnosing Syncope: Part 2: Unexplained Syncope , 1997, Annals of Internal Medicine.

[9]  A. Briggs,et al.  Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. , 2002, Health economics.

[10]  M Linzer,et al.  Diagnosing syncope. Part 2: Unexplained syncope. Clinical Efficacy Assessment Project of the American College of Physicians. , 1997, Annals of internal medicine.

[11]  Martin Knapp,et al.  Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: Randomised controlled trial , 2004, British Journal of Psychiatry.

[12]  B. Hanusa,et al.  The duration of Holter monitoring in patients with syncope. Is 24 hours enough? , 1990, Archives of internal medicine.

[13]  R. Robinson Economic Evaluation and Health Care Cost-effectiveness analysis , 2006 .

[14]  H Calkins,et al.  The economic burden of unrecognized vasodepressor syncope. , 1993, The American journal of medicine.

[15]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[16]  W. Kapoor,et al.  CLINICAL GUIDELINE: Diagnosing Syncope: Part 1: Value of History, Physical Examination, and Electrocardiography , 1997, Annals of Internal Medicine.

[17]  N. Zethraeus,et al.  Definition, interpretation and calculation of cost-effectiveness acceptability curves. , 2000, Health economics.

[18]  Anthony O'Hagan,et al.  INCORPORATION OF GENUINE PRIOR INFORMATION IN COST-EFFECTIVENESS ANALYSIS OF CLINICAL TRIAL DATA , 2002, International Journal of Technology Assessment in Health Care.

[19]  M Johannesson,et al.  A Note on Confidence Intervals in Cost-Effectiveness Analysis , 1998, International Journal of Technology Assessment in Health Care.

[20]  W. Kapoor,et al.  Prolonged electrocardiographic monitoring in patients with syncope. Importance of frequent or repetitive ventricular ectopy. , 1987, The American journal of medicine.

[21]  E. Prystowsky,et al.  Utility and cost of event recorders in the diagnosis of palpitations, presyncope, and syncope. , 1997, The American journal of cardiology.

[22]  A O'Hagan,et al.  A framework for cost-effectiveness analysis from clinical trial data. , 2001, Health economics.

[23]  M J Al,et al.  Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.

[24]  A. Krahn,et al.  The high cost of syncope: cost implications of a new insertable loop recorder in the investigation of recurrent syncope. , 1999, American heart journal.

[25]  M J Al,et al.  A Bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty. , 2000, Health economics.

[26]  John Mullahy,et al.  Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis , 1998 .

[27]  S. Goodman Introduction to Bayesian methods I: measuring the strength of evidence , 2005, Clinical trials.

[28]  W. Kapoor,et al.  CLINICAL GUIDELINE: Diagnosing Syncope: Part 1: Value of History, Physical Examination, and Electrocardiography , 1997, Annals of Internal Medicine.

[29]  M. Linzer,et al.  Syncope in a general hospital patient population. Usefulness of the radionuclide brain scan, electroencephalogram, and 24-hour Holter monitor. , 1983, New York state journal of medicine.

[30]  A. Skanes,et al.  A cost effective approach to the investigation of syncope: relative merit of different diagnostic strategies. , 1999, The Canadian journal of cardiology.

[31]  M. Josephson,et al.  Utility of patient-activated cardiac event recorders in general clinical practice. , 1997, The American journal of cardiology.

[32]  Andrew Briggs,et al.  Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. , 2004, Health economics.

[33]  Renke Maas,et al.  Diagnostic Yield of External Electrocardiographic Loop Recorders in Patients with Recurrent Syncope and Negative Tilt Table Test , 2003, Pacing and clinical electrophysiology : PACE.

[34]  Elisabeth Fenwick,et al.  Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation , 2006, BMC Health Services Research.

[35]  Allan C Skanes,et al.  Cost implications of testing strategy in patients with syncope: randomized assessment of syncope trial. , 2003, Journal of the American College of Cardiology.

[36]  W. Kapoor,et al.  Syncope of unknown origin. The need for a more cost-effective approach to its diagnosis evaluation. , 1982, JAMA.

[37]  A Briggs,et al.  Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. , 1998, Health economics.

[38]  M. A. Best Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .

[39]  Ary Goldberger,et al.  Diagnostic Yield and Optimal Duration of Continuous-Loop Event Monitoring for the Diagnosis of Palpitations: A Cost-Effectiveness Analysis , 1998, Annals of Internal Medicine.

[40]  D. Lam,et al.  Cost-effectiveness of relapse-prevention cognitive therapy for bipolar disorder: 30-month study. , 2005, The British journal of psychiatry : the journal of mental science.

[41]  A. Skanes,et al.  A prospective randomized comparison of loop recorders versus Holter monitors in patients with syncope or presyncope. , 2003, The American journal of medicine.